X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB Share Price   (REDY)

Here is the latest stock price and chart of Dr. Reddys. For more details, see the Dr. Reddys company fact sheet and quarterly results. For a sector overview, read our pharmaceuticals sector report.

REFRESH
Live BSE Quotes Oct 17, 2017 (Close)
Price (Rs)2,382.35 Open (Rs) 2,400.00 High (Rs) 2,408.75 Low (Rs) 2,375.00
% Change-0.62 Volume 14,986 Value (Rs) 35,729,379 52-Week H/L 3,394.95 / 1,901.65
Live NSE Quotes Oct 17, 2017 (Close)
Price (Rs)2,381.35 Open (Rs) 2,397.00 High (Rs) 2,397.00 Low (Rs) 2,375.50
% Change-0.92 Volume 307,110 Value (Rs) 731,973,934 52-Week H/L 3,399.90 / 1,901.15
Valuation
EPS (Rs)* 72.74 P/E Ratio (x) 32.75 Market Cap (Rs m) 394,779.22 P/BV (x) 3.22
  *Trailing 12 months earnings, excluding extraordinary / exceptional items. BSE Sensex | CNX Nifty

Charts
Dr. Reddys Share Price Chart (Rs) - 1 Year
Loading...
 
Peer Group:
Quote & Graph
     
 S&P BSE SENSEX 
PERIOD
Advanced Charts new


Today's Market

Share Markets in India End Flat; Cipla & Bharti Airtel Top Gainers(Closing)

Share markets in India ended flat ahead of key corporate results and as profit booking in index heavyweights capped gains.

Related Views On News

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Suven Lifesciences: Profits Decline due to Higher tax outgo in the quarter (Quarterly Results Update - Detailed)

Sep 22, 2017

Muted growth in CRAMS segment continues to impact topline.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

More Views on News

Most Popular

25 Things PM Modi Did Not Tell You About the Indian Economy(Vivek Kaul's Diary)

Oct 9, 2017

There are way too many data points out there which clearly show that all is not well with the Indian economy.

The Multibaggers that will Rise from the Ashes of Disruption(Smart Contrarian)

Oct 4, 2017

Of new age asset-light businesses and an Indian player that ticks all the right boxes.

Invest in a 'Haunted House' Stock and Make a Killing(The 5 Minute Wrapup)

Oct 7, 2017

You can make a killing by buying non-commodity business in a commodity industry

Nifty 50 Constituents Change...Once Again(Daily Profit Hunter)

Oct 4, 2017

Does it make sense to look at long term charts when the index constituents are changing frequently?

BSE IPO Index vis-a-vis Sensex(Chart Of The Day)

Oct 7, 2017

IPO's have failed to beat the benchmark index in the past decade.

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB 5-YR ANALYSIS

COMPARE DR. REDDYS LAB WITH

MARKET STATS